Patents Assigned to Rockefeller University
  • Pharmaceutical compositions comprising attenuated sporozoites and glycolipid adjuvants
    Patent number: 9642909
    Abstract: Disclosed herein are pharmaceutical compositions comprising Plasmodium sporozoite-stage parasites and compatible glycolipid adjuvants useful in vaccines for preventing or reducing the risk of malaria. In particular, human host range Plasmodium and analogues of ?-galactosylceramide (?-GalCer), a ligand for natural killer T (NKT) cells, are combined in pharmaceutical compositions, which are useful as vaccines against malaria. Methods of use are also provided.
    Type: Grant
    Filed: February 18, 2016
    Date of Patent: May 9, 2017
    Assignees: Sanaria Inc., The Rockefeller University
    Inventors: Sumana Chakravarty, Stephen L. Hoffman, Moriya Tsuji
  • Method of treating cancer
    Patent number: 9610319
    Abstract: A method of treating liver cancer using a peptide based on venom from a terebrid snail, terebrid variegata, is described. The venom has a general formula of TRX3CCGCYWNGSKDVCSQSCC (SEQ ID NO: 1) and variants thereof are described.
    Type: Grant
    Filed: September 30, 2015
    Date of Patent: April 4, 2017
    Assignees: Research Foundation of the City University of New York, The Rockefeller University
    Inventors: Mande Holford, Prachi Anand, Beatrix Ueberheide, Brian Chait
  • Regulatory proteins and inhibitors
    Patent number: 9605041
    Abstract: The invention provides a previously uncharacterized protein (gamma secretase activating protein or gSAP) that activates ?-secretase to produce ?-amyloid protein (A?). Deposition of A? has been associated with Alzheimer's disease and other pathologies. The invention thus additionally provides, e.g., screening methods and novel research tools, inhibitors of this novel protein, and methods of diagnosis, treatment and control of Alzheimer's disease and other neurodegenerative conditions associated with deposition of A?.
    Type: Grant
    Filed: February 6, 2012
    Date of Patent: March 28, 2017
    Assignees: INTRA-CELLULAR THERAPIES, INC., THE ROCKEFELLER UNIVERSITY
    Inventors: Paul Greengard, Wenjie Luo, Gen He, Peng Li, Lawrence Wennogle
  • Treatment of pancreatic and related cancers with 5-acyl-6,7-Dihydrothieno[3,2-C]pyridines
    Patent number: 9597320
    Abstract: Methods for inhibiting the growth of pancreatic cancer cells or other cancer cells driven by Sonic hedgehog are disclosed.
    Type: Grant
    Filed: January 22, 2016
    Date of Patent: March 21, 2017
    Assignees: Memorial Sloan-Kettering Cancer Center, The Rockefeller University
    Inventors: Marilyn D. Resh, Joseph Fraser Glickman, Elissaveta Petrova, Ouathek Ouerfelli
  • Non-sialylated anti-inflammatory polypeptides
    Patent number: 9587025
    Abstract: This invention concerns anti-inflammatory agents, compositions, and methods for treating inflammatory disorders.
    Type: Grant
    Filed: December 10, 2012
    Date of Patent: March 7, 2017
    Assignee: The Rockefeller University
    Inventors: Jeffrey V. Ravetch, Andrew Pincetic
  • Glycan-modified anti-CD4 antibody with improved HIV-1 neutralizing activity
    Patent number: 9587022
    Abstract: Disclosed herein are glycan-modified anti-CD4 monoclonal antibodies with N-linked glycans attached to the variable region. Expression vectors and cell lines useful for the production of such antibodies, and use of such antibodies for HIV prevention and therapy are also disclosed.
    Type: Grant
    Filed: December 18, 2013
    Date of Patent: March 7, 2017
    Assignee: THE ROCKEFELLER UNIVERSITY
    Inventors: Ruijiang Song, David D. Ho
  • Modification of recombinant adenovirus with immunogenic plasmodium circumsporozoite protein epitopes
    Patent number: 9555089
    Abstract: The present disclosure relates to adenovirus protein modifications to augment immune response to a transgene of a recombinant adenovirus and to circumvent pre-existing anti-adenovirus immunity. Some embodiments are directed to a recombinant adenovirus derived from a recombinant adenovirus plasmid vector, wherein the recombinant adenovirus plasmid vector comprises a nucleotide sequence encoding a Plasmodium circumsporozoite protein, or antigenic portion thereof, operably linked to a heterologous promoter and a modified capsid or core protein, wherein an immunogenic epitope of Plasmodium circumsporozoite is inserted into or replaces at least part of a capsid or core protein. Other embodiments are directed to a pharmaceutical composition or a malaria vaccine composition comprising a recombinant adenovirus according to the above embodiments.
    Type: Grant
    Filed: February 17, 2012
    Date of Patent: January 31, 2017
    Assignee: THE ROCKEFELLER UNIVERSITY
    Inventors: Takayuki Shiratsuchi, Moriya Tsuji
  • Methods for the treatment of A-? related disorders and compositions therefor
    Patent number: 9532980
    Abstract: The invention provides methods for treating A? peptide related disorders such as Alzheimer's disease comprising administering a therapeutically effective amount of a CK1 modulator to a patient in need thereof.
    Type: Grant
    Filed: October 24, 2007
    Date of Patent: January 3, 2017
    Assignee: The Rockefeller University
    Inventors: Marc Flajolet, Paul Greengard
  • Oxadiazolo[3,2-A]pyrimidines and thiadiazolo[3,2-A]pyrimidines
    Patent number: 9532989
    Abstract: The present invention relates to compounds of Formula P-I where the variables (e.g. R1, Y, A, R1, Ra, Ra?, Rb, Rb?, Rc, Rc?, Rd, Rd?, Re, or Re?) and compositions useful for inhibiting and/or reducing platelet deposition, adhesion and/or aggregation. The present invention further relates to methods for the treatment or prophylaxis of thrombotic disorders, including stroke, myocardial infarction, unstable angina, peripheral vascular disease, abrupt closure following angioplasty or stent placement and thrombosis as a result of vascular surgery.
    Type: Grant
    Filed: June 4, 2015
    Date of Patent: January 3, 2017
    Assignees: THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI, THE ROCKEFELLER UNIVERSITY
    Inventors: Barry S. Coller, Craig Thomas, Marta Filizola, Joshua McCoy, Wenwei Huang, Min Shen
  • ANTIBODIES TO CD40 WITH ENHANCED AGONIST ACTIVITY
    Publication number: 20160376371
    Abstract: Provided herein are agonistic antibodies, or antigen binding portions thereof, that bind to human CD40. Such antibodies optionally comprise Fc regions with enhanced specificity for Fc?RIIb. The invention also provides methods of treatment of cancer or chronic infection by administering the antibodies of the invention to a subject in need thereof.
    Type: Application
    Filed: June 28, 2016
    Publication date: December 29, 2016
    Applicants: The Rockefeller University, BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Jeffrey V. Ravetch, Rony Dahan, Bryan C. Barnhart, Brigitte Devaux, Aaron P. Yamniuk, Shannon L. Okada, Brenda L. Stevens
  • Treatment and diagnosis of melanoma
    Patent number: 9526710
    Abstract: The present invention discloses novel agents and methods for diagnosis and treatment of melanoma. Also disclosed are related arrays, kits, and screening methods.
    Type: Grant
    Filed: September 15, 2014
    Date of Patent: December 27, 2016
    Assignee: THE ROCKEFELLER UNIVERSITY
    Inventors: Sohail Tavazoie, Nora Pencheva
  • TREATMENT AND DIAGNOSIS OF MELANOMA
    Publication number: 20160331726
    Abstract: The present invention discloses novel agents and methods for diagnosis and treatment of melanoma. Also disclosed are related arrays, kits, and screening methods.
    Type: Application
    Filed: August 4, 2016
    Publication date: November 17, 2016
    Applicant: The Rockefeller University
    Inventors: Sohail F. Tavazoie, Nora Pencheva
  • Treatment of angiogenesis disorders
    Patent number: 9493841
    Abstract: This invention concerns pathological angiogenesis and cancer, related treatment methods, and related compositions. Also disclosed are related diagnosis kits and methods.
    Type: Grant
    Filed: March 16, 2015
    Date of Patent: November 15, 2016
    Assignee: The Rockefeller University
    Inventors: Sohail Tavazoie, Nils Halberg, Kim Png
  • Antibodies directed toward the HIV-1 GP120 CD4 binding site with increased potency and breadth
    Patent number: 9493549
    Abstract: Embodiments of the present invention are directed to compositions and methods for anti-HIV (anti-CD4 binding site) potent VRC01-like (PVL) antibodies targeted to gp120 having an amino acid substitution in the heavy chain at a residue in the anti-CD4 binding site PVL antibody that is equivalent to Phe43 in CD4 and an amino acid substitution in the light chain, these antibodies having improved potency and breadth.
    Type: Grant
    Filed: December 13, 2012
    Date of Patent: November 15, 2016
    Assignees: THE ROCKEFELLER UNIVERSITY, CALIFORNIA INSTITUTE OF TECHNOLOGY
    Inventors: Ron Diskin, Pamela J. Bjorkman, Michel Nussenzweig, Johannes Scheid
  • Treatment and diagnosis of colon cancer
    Patent number: 9492414
    Abstract: The present invention discloses novel agents and methods for diagnosis and treatment of colon cancer. Also disclosed are related arrays, kits, and screening methods.
    Type: Grant
    Filed: May 7, 2015
    Date of Patent: November 15, 2016
    Assignee: The Rockefeller University
    Inventors: Sohail Tavazoie, Jia M. Loo
  • ANTIBODIES SPECIFIC FOR THE PROTOFIBRIL FORM OF BETA-AMYLOID PROTEIN
    Publication number: 20160319006
    Abstract: Isolated antibodies have been characterized which show specific affinity to a repeating conformational epitope of a protofibril form of the human ?-amyloid peptide as compare to low molecular weight forms of ?-amyloid peptide. These isolated antibodies and related pharmaceutically effective compositions may be useful in the therapeutic and/or prophylactic treatment of Alzheimer's disease by effectively blocking the ability of the protofibril form of ?-amyloid peptide to form fibril forms linked with complications associated with Alzheimer's disease. The isolated antibodies of the present invention are also useful in various diagnostic assays and associated kits.
    Type: Application
    Filed: May 16, 2016
    Publication date: November 3, 2016
    Applicant: The Rockefeller University
    Inventors: Jeffrey V. Ravetch, Hidehiro Fukuyama
  • ANTI-INFLAMMATORY POLYPEPTIDES
    Publication number: 20160319024
    Abstract: This invention concerns anti-inflammatory agents, compositions, and methods for treating inflammatory disorders.
    Type: Application
    Filed: March 4, 2015
    Publication date: November 3, 2016
    Applicant: THE ROCKEFELLER UNIVERSITY
    Inventors: Jeffrey V. Ravetch, Andrew Pincetic
  • hDC-sign binding peptides
    Patent number: 9481724
    Abstract: Polypeptides that bind to DC-SIGN and/or its homologues and methods for using such peptides for the treatment of various disorders are described. DC-SIGN and its homologues are receptors that bind IgG antibodies or Fc fragments and mediate intravenous immunoglobulin (IVIG)-related reversal of inflammation associated with various immune disorders.
    Type: Grant
    Filed: December 10, 2012
    Date of Patent: November 1, 2016
    Assignees: The Rockefeller University, Sloan-Kettering Institute for Cancer Research
    Inventors: Jeffrey Ravetch, Andrew Pincetic, Ping Wang, Sam Danishefsky
  • Anticancer agents of the anthracyclin family
    Patent number: 9475834
    Abstract: Anthracyclin compounds of the general structure: are disclosed. In these compounds R1 is methyl, acetyl or hydroxyacetyl; R2—R5 and R10—R13 are independently H or methyl; R6 R7 and R8 are independently H, OH or OCH3; and n is zero or one. The compounds are useful for treating cancer.
    Type: Grant
    Filed: November 13, 2015
    Date of Patent: October 25, 2016
    Assignee: The Rockefeller University
    Inventors: Sean Brady, Hahk-Soo Kang
  • DNA virus MicroRNA and methods for inhibiting same
    Patent number: 9476048
    Abstract: The invention relates to isolated nucleic acid molecules comprising the sequence of a human cytomegalovirus microRNA. In another embodiment, the invention relates to single stranded DNA virus microRNA molecules comprising the sequence of a human cytomegalovirus microRNA. The invention also relates to the anti-DNA virus microRNA molecules.
    Type: Grant
    Filed: November 30, 2011
    Date of Patent: October 25, 2016
    Assignee: The Rockefeller University
    Inventors: Sebastien Pfeffer, Thomas Tuschl